Sydney, Australia (CU)_ Australians with moderate-to-severe ulcerative colitis (UC) now can avail a PBS-listed oral treatment, which is an alternative therapy. Xeljanz (tofacitinib citrate) is a Janus kinase (JAK) inhibitor that suppresses immune system activation in autoimmune diseases including ulcerative colitis and other inflammatory illnesses. Ulcerative colitis is one of the primary inflammatory bowel illnesses impacting around 87,000 Australians and is marked by chronic inflammation of the large intestine’s internal lining. It might result in bleeding, diarrhoea, bowel urgency, stomach pain, exhaustion, and weight loss.
According to data from…
